Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed neuroblastoma (NBL) or ganglioneuroblastoma with tumor-associated opsoclonus-myoclonus-ataxia syndrome (OMA)~  * Patients with NBL diagnosed within 6 months of OMA diagnosis AND patients with OMA diagnosed within 6 months of NBL diagnosis are eligible~ * Must enroll on study within 4 weeks of diagnosis~ * Presence of opsoclonus, myoclonus, and/or ataxia associated with neuroblastoma considered eligible~* Currently enrolled on COG neuroblastoma protocols: COG-ANBL00B1 or its successor~* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows:~  * ≤ 0.4 mg/dL (for patients 1 to 5 months of age)~ * ≤ 0.5 mg/dL (for patients 6 to 11 months of age)~ * ≤ 0.6 mg/dL (for patients 1 year of age)~ * ≤ 0.8 mg/dL (for patients 2 to 5 years of age)~ * ≤ 1.0 mg/dL (for patients 6 to 9 years of age)~ * ≤ 1.2 mg/dL (for patients 10 to 12 years of age)~ * ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)~ * ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)~ * ≤ 1.6 mg/dL (for male patients ≥ 16 years of age)~* No prior IV gamma globulin therapy~* No prior chemotherapy~* Concurrent chemotherapy allowed~* No prior prednisone or corticotropin~  * Patients who have received ≤ 14 days of steroids are eligible~* Concurrent surgery allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (chemotherapy, immunoglobulin therapy) (Type: EXPERIMENTAL): Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients receive immune globulin IV on days -2 and -1, at weeks 4, 8, 12, 16, 20, and 24, and then at months 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment.
- Arm II (chemotherapy, observation) (Type: ACTIVE_COMPARATOR): Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients do not receive immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).